Study
Classic DesignHigh ImpactStrong effect

CTCA offers comparable patient outcomes to traditional angiography at a significantly lower cost.

Advanced diagnostic imaging technology can achieve similar or better functional outcomes than established methods while reducing overall expenditure.

Circulation Journal · 2009

01

Key Findings

  • 01CTCA gained 0.551 QALYs with an ICER of US$15,581 per QALY compared to no examination and no treatment strategies.
  • 02Routine CAG gained only 0.012 QALYs compared to CTCA, with a much higher ICER of US$445,276 per QALY.
  • 03CTCA achieved comparable QALY gains to routine CAG but at a lower cost.
02

Application

Design takeaway

When developing new diagnostic or treatment technologies, prioritize not only efficacy but also cost-effectiveness and the potential to replace less efficient, established methods.

How to apply

When evaluating a new design, consider its cost-effectiveness compared to existing solutions and quantify the potential for improved patient outcomes or reduced healthcare system costs.

Project actions

  • 01When researching existing products or solutions, look for studies that compare them on both performance and cost.
  • 02Consider how your design project could offer a more efficient or cost-effective alternative to current methods.
03

Method & Evidence

AimTo compare the lifetime benefits and cost-effectiveness of using computed tomographic coronary angiography (CTCA) versus traditional coronary angiography (CAG) and other strategies for diagnosing stable coronary artery disease.
MethodCost-utility and cost-effectiveness analysis using a Markov model.
ProcedureA Markov model was developed to simulate four diagnostic strategies over a lifetime for individuals at risk of stable coronary artery disease: no examination, routine coronary angiography (CAG), CTCA, and medication without invasive examination. The model evaluated quality-adjusted life-years (QALYs) gained and incremental cost-effectiveness ratios (ICERs).
ContextMedical diagnostics for coronary artery disease.

Variables

IVDiagnostic strategy (No examination, Routine CAG, CTCA, Medication only).
DVQuality-Adjusted Life-Years (QALYs) gained, Incremental Cost-Effectiveness Ratio (ICER).
CVPatient population at risk for stable coronary artery disease, lifetime horizon.
04

Strengths & Limitations

Strengths

  • +Comprehensive lifetime analysis.
  • +Comparison of multiple diagnostic strategies.

Limitations

The cost data is from 2007, so current costs might differ. The model simplifies complex medical pathways.

Reliability & validity

The validity of the Markov model depends on the accuracy of the input data and assumptions regarding disease progression and costs. The reliability would be in the consistency of the model's output given the same inputs.

Think critically

How might the 'cost' of a diagnostic tool be defined beyond direct monetary expenditure (e.g., patient time, radiation exposure)?

05

Design Principles

"Technological innovation should aim for both improved performance and economic efficiency."

This research highlights how technological advancements in diagnostic tools can lead to more efficient healthcare delivery. Designers and engineers can learn from this by focusing on how new technologies can not only improve performance but also address economic constraints, making advanced solutions more accessible.

06

What This Means for Your Design

New medical scanning technology (CTCA) is better and cheaper than the old way (CAG) for checking heart problems.

How to use in your project

  • 1.Reference this study when discussing the evaluation of alternative design solutions, particularly focusing on cost-benefit analysis or the comparison of established versus novel approaches.
07

Add to My Project

08

Quick Cite

(2009). Computed Tomographic Coronary Angiography for Diagnosing Stable Coronary Artery Disease A Cost-Utility and Cost-Effectiveness Analysis. Circulation Journal. https://doi.org/10.1253/circj.cj-08-1186 Retrieved from https://designdex.org/study/acb110e8-d09b-4cdf-af78-6edf8c608f53/ctca-offers-comparable-patient-outcomes-to-traditional-angiography-at-a-significantly-lower-cost

Paragraph starter

This research demonstrates that advancements in diagnostic technology, such as CTCA, can provide comparable or superior patient outcomes to established methods like traditional angiography, while also offering significant cost savings. This principle of achieving greater value through technological innovation is crucial when evaluating design alternatives, suggesting that new designs should be assessed not only on their performance but also on their economic viability and potential to optimize resource utilization within a system.

09

Source

Circulation Journal

Computed Tomographic Coronary Angiography for Diagnosing Stable Coronary Artery Disease A Cost-Utility and Cost-Effectiveness Analysis

journal · 2009

View source

Questions about this research

What does the research say about ctca offers comparable patient outcomes to traditional angiography at a significantly lower cost?
When developing new diagnostic or treatment technologies, prioritize not only efficacy but also cost-effectiveness and the potential to replace less efficient, established methods. Evidence: Circulation Journal (2009).
Why does "CTCA offers comparable patient outcomes to traditional angiography at a significantly lower cost." matter for design?
This research highlights how technological advancements in diagnostic tools can lead to more efficient healthcare delivery. Designers and engineers can learn from this by focusing on how new technologies can not only improve performance but also address economic constraints, making advanced solutions more accessible.
How can designers apply this research?
When developing new diagnostic or treatment technologies, prioritize not only efficacy but also cost-effectiveness and the potential to replace less efficient, established methods.
What were the main findings?
CTCA gained 0.551 QALYs with an ICER of US$15,581 per QALY compared to no examination and no treatment strategies.. Routine CAG gained only 0.012 QALYs compared to CTCA, with a much higher ICER of US$445,276 per QALY.. CTCA achieved comparable QALY gains to routine CAG but at a lower cost.
What research method was used?
Cost-utility and cost-effectiveness analysis using a Markov model..
How strong is the evidence?
Evidence strength is rated Strong effect, based on a 2009 journal from Circulation Journal.
What should I do differently in my next project?
When evaluating a new design, consider its cost-effectiveness compared to existing solutions and quantify the potential for improved patient outcomes or reduced healthcare system costs.
What are the limitations?
The analysis is based on a Markov model and may not capture all real-world complexities. Cost data is from 2007.
Is there evidence that coronary artery affects design outcomes?
Using CTCA as a first-line diagnostic tool for coronary artery disease provides similar health benefits to traditional methods but is significantly more cost-effective. This research highlights how technological advancements in diagnostic tools can lead to more efficient healthcare delivery. Designers and engineers can Source: Circulation Journal (2009).
Where does this artery disease research apply?
Medical diagnostics for coronary artery disease. It sits within classic design research on designdex.org.

Related research topics

coronary artery design research · evidence on coronary artery · does coronary artery improve design outcomes · artery disease studies for designers · coronary artery and artery disease findings · classic design research evidence